Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 20/20 | 0.64 |
| ▸ | EDNRB | P24530 | 13/20 | 0.64 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.64 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.64 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | DHPS | P49366 | 1/20 | 0.64 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.64 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13430586 | 0.96 | EDNRA (0.61) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL29770411 | 0.94 | EDNRA (0.72) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL617288 | 0.94 | EDNRA (0.72) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL5686011 | 0.93 | EDNRA (0.71) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL625550 | 0.93 | EDNRA (0.71) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL13430582 | 0.91 | EDNRA (0.64) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL1259727 | 0.88 | EDNRA (0.69) | EDNRAEDNRB | |
| SCHEMBL16900663 | 0.87 | EDNRA (0.70) | EDNRAEDNRB | |
| SCHEMBL1938981 | 0.87 | EDNRA (0.78) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7293756 | 0.86 | EDNRA (0.62) | EDNRAEDNRBABCC3ABCC4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080549-B2 | Endothelin receptor antagonists | CONCERT PHARMACEUTICALS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20100063076-A1 | Endothelin receptor antagonists | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2010-03-11 | — | — | US | disclosed |
| US-20100063076-A1 | Endothelin receptor antagonists | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2010-03-11 | — | — | US | disclosed |
| US-20090005394-A1 | Endothelin receptor antagonists | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063076-A1 | Endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885ABCC3 2047/4885 |
| US-20090005394-A1 | Endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885ABCC3 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.